Ralf E Harskamp1, John H Alexander2, Phillip J Schulte2, Colleen M Brophy3, Michael J Mack4, Eric D Peterson2, Judson B Williams2, C Michael Gibson5, Robert M Califf6, Nicholas T Kouchoukos7, Robert A Harrington8, T Bruce Ferguson9, Renato D Lopes2. 1. Department of Medicine, Duke Clinical Research Institute, Duke University, Durham, North Carolina2Heart Center, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. 2. Department of Medicine, Duke Clinical Research Institute, Duke University, Durham, North Carolina. 3. Division of Vascular Surgery, Vanderbilt University, Nashville, Tennessee. 4. Cardiopulmonary Research Science and Technology Institute, Dallas, Texas. 5. PERFUSE Angiographic Laboratory, Boston, Massachusetts. 6. Department of Medicine, Duke Translational Medicine Institute, Duke University, Durham, North Carolina. 7. Heart Center, Missouri Baptist Medical Center, St Louis, Missouri. 8. Department of Medicine, Stanford University, Stanford, California. 9. Department of Cardiovascular Sciences, East Carolina University, Greenville, North Carolina.
Abstract
IMPORTANCE: In vitro and animal model data suggest that intraoperative preservation solutions may influence endothelial function and vein graft failure (VGF) after coronary artery bypass graft (CABG) surgery. Clinical studies to validate these findings are lacking. OBJECTIVE: To evaluate the effect of vein graft preservation solutions on VGF and clinical outcomes in patients undergoing CABG surgery. DESIGN, SETTING, AND PARTICIPANTS: Data from the Project of Ex-Vivo Vein Graft Engineering via Transfection IV (PREVENT IV) study, a phase 3, multicenter, randomized, double-blind, placebo-controlled trial that enrolled 3014 patients at 107 US sites from August 1, 2002, through October 22, 2003, were used. Eligibility criteria for the trial included CABG surgeryfor coronary artery disease with at least 2 planned vein grafts. INTERVENTIONS: Preservation of vein grafts in saline, blood, or buffered saline solutions. MAIN OUTCOMES AND MEASURES: One-year angiographic VGF and 5-year rates of death, myocardial infarction, and subsequent revascularization. RESULTS: Most patients had grafts preserved in saline (1339 [44.4%]), followed by blood (971 [32.2%]) and buffered saline (507 [16.8%]). Baseline characteristics were similar among groups. One-year VGF rates were much lower in the buffered saline group than in the saline group (patient-level odds ratio [OR], 0.59 [95% CI, 0.45-0.78; P < .001]; graft-level OR, 0.63 [95% CI, 0.49-0.79; P < .001]) or the blood group (patient-level OR, 0.62 [95% CI, 0.46-0.83; P = .001]; graft-level OR, 0.63 [95% CI, 0.48-0.81; P < .001]). Use of buffered saline solution also tended to be associated with a lower 5-year risk for death, myocardial infarction, or subsequent revascularization compared with saline (hazard ratio, 0.81 [95% CI, 0.64-1.02; P = .08]) and blood (0.81 [0.63-1.03; P = .09]) solutions. CONCLUSIONS AND RELEVANCE: Patients undergoing CABG whose vein grafts were preserved in a buffered saline solution had lower VGF rates and trends toward better long-term clinical outcomes compared with patients whose grafts were preserved in saline- or blood-based solutions. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00042081.
RCT Entities:
IMPORTANCE: In vitro and animal model data suggest that intraoperative preservation solutions may influence endothelial function and vein graft failure (VGF) after coronary artery bypass graft (CABG) surgery. Clinical studies to validate these findings are lacking. OBJECTIVE: To evaluate the effect of vein graft preservation solutions on VGF and clinical outcomes in patients undergoing CABG surgery. DESIGN, SETTING, AND PARTICIPANTS: Data from the Project of Ex-Vivo Vein Graft Engineering via Transfection IV (PREVENT IV) study, a phase 3, multicenter, randomized, double-blind, placebo-controlled trial that enrolled 3014 patients at 107 US sites from August 1, 2002, through October 22, 2003, were used. Eligibility criteria for the trial included CABG surgery for coronary artery disease with at least 2 planned vein grafts. INTERVENTIONS: Preservation of vein grafts in saline, blood, or buffered saline solutions. MAIN OUTCOMES AND MEASURES: One-year angiographic VGF and 5-year rates of death, myocardial infarction, and subsequent revascularization. RESULTS: Most patients had grafts preserved in saline (1339 [44.4%]), followed by blood (971 [32.2%]) and buffered saline (507 [16.8%]). Baseline characteristics were similar among groups. One-year VGF rates were much lower in the buffered saline group than in the saline group (patient-level odds ratio [OR], 0.59 [95% CI, 0.45-0.78; P < .001]; graft-level OR, 0.63 [95% CI, 0.49-0.79; P < .001]) or the blood group (patient-level OR, 0.62 [95% CI, 0.46-0.83; P = .001]; graft-level OR, 0.63 [95% CI, 0.48-0.81; P < .001]). Use of buffered saline solution also tended to be associated with a lower 5-year risk for death, myocardial infarction, or subsequent revascularization compared with saline (hazard ratio, 0.81 [95% CI, 0.64-1.02; P = .08]) and blood (0.81 [0.63-1.03; P = .09]) solutions. CONCLUSIONS AND RELEVANCE: Patients undergoing CABG whose vein grafts were preserved in a buffered saline solution had lower VGF rates and trends toward better long-term clinical outcomes compared with patients whose grafts were preserved in saline- or blood-based solutions. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00042081.
Authors: Domingos S R Souza; Michael R Dashwood; Janice C S Tsui; Derek Filbey; Lennart Bodin; Benny Johansson; Jan Borowiec Journal: Ann Thorac Surg Date: 2002-04 Impact factor: 4.330
Authors: John H Alexander; T Bruce Ferguson; Diane M Joseph; Michael J Mack; Randall K Wolf; C Michael Gibson; Daniel Gennevois; Todd J Lorenz; Robert A Harrington; Eric D Peterson; Kerry L Lee; Robert M Califf; Nicholas T Kouchoukos Journal: Am Heart J Date: 2005-10 Impact factor: 4.749
Authors: Saswata Deb; Eric A Cohen; Steve K Singh; Dai Une; Andreas Laupacis; Stephen E Fremes Journal: J Am Coll Cardiol Date: 2012-07-03 Impact factor: 24.094
Authors: Andrzej Dumanski; Miroslaw Sopel; Marek Pelczar; Michał Szłapka; Wojciech Kustrzycki; Maciej Zabel Journal: In Vivo Date: 2007 Sep-Oct Impact factor: 2.155
Authors: F P Catinella; J N Cunningham; R K Srungaram; F G Baumann; I M Nathan; E A Glassman; E A Knopp; F C Spencer Journal: J Thorac Cardiovasc Surg Date: 1982-05 Impact factor: 5.209
Authors: Renato D Lopes; Judson B Williams; Rajendra H Mehta; Eric M Reyes; Gail E Hafley; Keith B Allen; Michael J Mack; Eric D Peterson; Robert A Harrington; C Michael Gibson; Robert M Califf; Nicholas T Kouchoukos; T Bruce Ferguson; Todd J Lorenz; John H Alexander Journal: Am Heart J Date: 2012-09 Impact factor: 4.749
Authors: Eric S Wise; Kyle M Hocking; Susan Eagle; Tarek Absi; Padmini Komalavilas; Joyce Cheung-Flynn; Colleen M Brophy Journal: Surgery Date: 2015-05-21 Impact factor: 3.982
Authors: Eric S Wise; Kyle M Hocking; Daniel Feldman; Padmini Komalavilas; Joyce Cheung-Flynn; Colleen M Brophy Journal: Am Surg Date: 2015-07 Impact factor: 0.688
Authors: Walid Ben Ali; Pierre Voisine; Peter Skov Olsen; Hugues Jeanmart; Nicolas Noiseux; Tracy Goeken; Vilas Satishchandran; Filippo Cademartiri; Garry Cutter; Dave Veerasingam; Craig Brown; Maximilian Y Emmert; Louis P Perrault Journal: Open Heart Date: 2018-04-13
Authors: Michael Sobel; Shinsuke Kikuchi; Lihua Chen; Gale L Tang; Tom N Wight; Richard D Kenagy Journal: J Vasc Surg Date: 2018-06-15 Impact factor: 4.268
Authors: Margreet R de Vries; Karin H Simons; J Wouter Jukema; Jerry Braun; Paul H A Quax Journal: Nat Rev Cardiol Date: 2016-05-19 Impact factor: 32.419
Authors: Eric S Wise; Kyle M Hocking; Weifeng Luo; Daniel L Feldman; Jun Song; Padmini Komalavilas; Joyce Cheung-Flynn; Colleen M Brophy Journal: Vasc Med Date: 2016-05-23 Impact factor: 3.239
Authors: Etem Caliskan; Domingos Ramos de Souza; Andreas Böning; Oliver J Liakopoulos; Yeong-Hoon Choi; John Pepper; C Michael Gibson; Louis P Perrault; Randall K Wolf; Ki-Bong Kim; Maximilian Y Emmert Journal: Nat Rev Cardiol Date: 2019-08-27 Impact factor: 32.419
Authors: Joyce Cheung-Flynn; Jun Song; Igor Voskresensky; Eric S Wise; Yapu Liu; Yanhua Xiong; Susan S Eagle; Colleen M Brophy; C Robb Flynn Journal: Sci Rep Date: 2017-10-27 Impact factor: 4.379